Single-cell transcriptomics reveal metastatic CLDN4+ cancer cells underlying the recurrence of malignant pleural effusion in patients with advanced non-small-cell lung cancer

Abstract

Background: Recurrent malignant pleural effusion (MPE) resulting from non-small-cell lung cancer (NSCLC) is easily refractory to conventional therapeutics and lacks predictive markers. The cellular or genetic signatures of recurrent MPE still remain largely uncertain.

Methods: 16 NSCLC patients with pleural effusions were recruited, followed by corresponding treatments based on primary tumours. Non-recurrent or recurrent MPE was determined after 3-6 weeks of treatments. The status of MPE was verified by computer tomography (CT) and cytopathology, and the baseline pleural fluids were collected for single-cell RNA sequencing (scRNA-seq). Samples were then integrated and profiled. Cellular communications and trajectories were inferred by bioinformatic algorithms. Comparative analysis was conducted and the results were further validated by quantitative polymerase chain reaction (qPCR) in a larger MPE cohort from the authors' centre (n = 64).

Results: The scRNA-seq revealed that 33 590 cells were annotated as 7 major cell types and further characterized into 14 cell clusters precisely. The cell cluster C1, classified as Epithelial Cell Adhesion Molecule (EpCAM)+ metastatic cancer cell and correlated with activation of tight junction and adherence junction, was significantly enriched in the recurrent MPE group, in which Claudin-4 (CLDN4) was identified. The subset cell cluster C3 of C1, which was enriched in recurrent MPE and demonstrated a phenotype of ameboidal-type cell migration, also showed a markedly higher expression of CLDN4. Meanwhile, the expression of CLDN4 was positively correlated with E74 Like ETS Transcription Factor 3 (ELF3), EpCAM and Tumour Associated Calcium Signal Transducer 2 (TACSTD2), independent of driver-gene status. CLDN4 was also found to be associated with the expression of Hypoxia Inducible Factor 1 Subunit Alpha (HIF1A) and Vascular Endothelial Growth Factor A (VEGFA), and the cell cluster C1 was the major mediator in cellular communication of VEGFA signalling. In the extensive MPE cohort, a notably increased expression of CLDN4 in cells from pleural effusion among patients diagnosed with recurrent MPE was observed, compared with the non-recurrent group, which was also associated with a trend towards worse overall survival (OS).

Conclusions: CLDN4 could be considered as a predictive marker of recurrent MPE among patients with advanced NSCLC. Further validation for its clinical value in cohorts with larger sample size and in-depth mechanism studies on its biological function are warranted.

Trial registration: Not applicable.

Keywords

disseminated tumour cells / malignant pleural effusion / metastasis / non-small-cell lung cancer / predictive marker / single-cell RNA sequencing

References

[1] McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumour marker prognostic studies (REMARK). Eur J Cancer. 2005;41(12):1690-1696.

[2] Donnenberg AD, Luketich JD, Dhupar R, et al. Treatment of malignant pleural effusions: the case for localized immunotherapy. J Immunother Cancer. 2019;7(1):110.

[3] Feller-Kopman D, Light R. Pleural disease. N Engl J Med. 2018;378(8):740-751.

[4] Mishra EK, Muruganandan S, Clark A, et al. Breathlessness Predicts survival in patients with malignant pleural effusions: meta-analysis of individual patient data from five randomized controlled trials. Chest. 2021;160(1):351-357.

[5] Kumar A, Xu B, Srinivasan D, et al. Long-term survival of American Joint Committee on Cancer 8th edition staging descriptors for clinical M1a non-small-cell lung cancer. Chest. 2023;165(3):725-737.

[6] Semaan R, Feller-Kopman D, Slatore C, et al. Malignant pleural effusions. Am J Respir Crit Care Med. 2016;194(6):P11-P12.

[7] Jacobs B, Sheikh G, Youness HA, et al. Diagnosis and management of malignant pleural effusion: a decade in review. Diagnostics (Basel). 2022;12(4):1016.

[8] Gayen S. Malignant pleural effusion: presentation, diagnosis, and management. Am J Med. 2022;135(10):1188-1192.

[9] Muruganandan S, Azzopardi M, Fitzgerald DB, et al. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respir Med. 2018;6(9):671-680.

[10] Lentz RJ, Lerner AD, Pannu JK, et al. Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial. Lancet Respir Med. 2019;7(5):447-455.

[11] Bhatnagar R, Piotrowska HEG, Laskawiec-Szkonter M, et al. Effect of thoracoscopic talc poudrage vs talc slurry via chest tube on pleurodesis failure rate among patients with malignant pleural effusions: a randomized clinical trial. JAMA. 2020;323(1):60-69.

[12] Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med. 2012;186(6):487-492.

[13] Changchien CY, Chen Y, Chang HH, et al. Effect of malignant-associated pleural effusion on endothelial viability, motility and angiogenesis in lung cancer. Cancer Sci. 2020;111(10):3747-3758.

[14] Giannou AD, Marazioti A, Spella M, et al. Mast cells mediate malignant pleural effusion formation. J Clin Invest. 2015;125(6):2317-2334.

[15] Niu Y, Zhou Q. Th17 cells and their related cytokines: vital players in progression of malignant pleural effusion. Cell Mol Life Sci. 2022;79(4):194.

[16] Wu XZ, Shi XY, Zhai K, et al. Activated naïve B cells promote development of malignant pleural effusion by differential regulation of T(H)1 and T(H)17 response. Am J Physiol Lung Cell Mol Physiol. 2018;315(3):L443-L455.

[17] Chen Y, Mathy NW, Lu H. The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non‑small cell lung cancer (Review). Mol Med Rep. 2018;17(6):8019-8030.

[18] Hsu LH, Soong TC, Chu NM, et al. The inflammatory cytokine profile of patients with malignant pleural effusion treated with pleurodesis. J Clin Med. 2020;9(12):4010.

[19] Wang D, Yang L, Yue D, et al. Macrophage-derived CCL22 promotes an immunosuppressive tumor microenvironment via IL-8 in malignant pleural effusion. Cancer Lett. 2019;452:244-253.

[20] Li X, Wu G, Chen C, et al. Intrapleural injection of anti-PD1 antibody: a novel management of malignant pleural effusion. Front Immunol. 2021;12:760683.

[21] Xiang Z, Deng X, He W, et al. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy. Ann Med. 2022;54(1):1357-1371.

[22] Zhang C, Zhang J, Xu FP, et al. Genomic landscape and immune microenvironment features of preinvasive and early invasive lung adenocarcinoma. J Thorac Oncol. 2019;14(11):1912-1923.

[23] Feller-Kopman DJ, Reddy CB, DeCamp MM, et al. Management of malignant pleural effusions: an official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med. 2018;198(7):839-849.

[24] Luo L, Deng S, Tang W, et al. Recruitment of IL-1β-producing intermediate monocytes enhanced by C5a contributes to the development of malignant pleural effusion. Thorac Cancer. 2022;13(6):811-823.

[25] Hardak E, Peled E, Crispel Y, et al. Heparan sulfate chains contribute to the anticoagulant milieu in malignant pleural effusion. Thorax. 2020;75(2):143-152.

[26] Kosti CN, Vaitsi PC, Pappas AG, et al. CSF1/CSF1R signaling mediates malignant pleural effusion formation. JCI Insight. 2022;7(6):e155300.

[27] Wang ZH, Zhang P, Peng WB, et al. Altered phenotypic and metabolic characteristics of FOXP3(+)CD3(+)CD56(+) natural killer T (NKT)-like cells in human malignant pleural effusion. Oncoimmunology. 2023;12(1):2160558.

[28] Hao S, Yang C, Song P, et al. CLDN4 promotes growth of acute myeloid leukemia cells via regulating AKT and ERK1/2 signaling. Biochem Biophys Res Commun. 2022;619:137-143.

[29] Ost DE, Niu J, Zhao H, et al. Quality gaps and comparative effectiveness of management strategies for recurrent malignant pleural effusions. Chest. 2018;153(2):438-452.

[30] Grosu HB, Molina S, Casal R, et al. Risk factors for pleural effusion recurrence in patients with malignancy. Respirology. 2019;24(1):76-82.

[31] Xu K, Wu X, Chen L, et al. Risk factors for symptomatic malignant pleural effusion recurrence in patients with actionable mutations in advanced lung adenocarcinoma. Transl Lung Cancer Res. 2023;12(9):1887-1895.

[32] Schwalk AJ, Ost DE, Saltijeral SN, et al. Risk factors for and time to recurrence of symptomatic malignant pleural effusion in patients with metastatic non-small cell lung cancer with EGFR or ALK mutations. Chest. 2021;159(3):1256-1264.

[33] Hughes SM, Carmichael JJ. Malignant pleural effusions: updates in diagnosis and management. Life (Basel). 2022;13(1):115.

[34] Wu F, Fan J, He Y, et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer. Nat Commun. 2021;12(1):2540.

[35] Keenan AB, Torre D, Lachmann A, et al. ChEA3: transcription factor enrichment analysis by orthogonal omics integration. Nucleic Acids Res. 2019;47(W1):W212-W224.

[36] Oughtred R, Rust J, Chang C, et al. The BioGRID database: a comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci. 2021;30(1):187-200.

[37] Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.

[38] Jin S, Guerrero-Juarez CF, Zhang L, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12(1):1088.

[39] James NE, Emerson JB, Borgstadt AD, et al. The biomarker HE4 (WFDC2) promotes a pro-angiogenic and immunosuppressive tumor microenvironment via regulation of STAT3 target genes. Sci Rep. 2020;10(1):8558.

[40] Mo L, Yu Z, Lv Y, et al. Single-cell RNA sequencing of metastatic testicular seminoma reveals the cellular and molecular characteristics of metastatic cell lineage. Front Oncol. 2022;12:871489.

[41] Lee CC, Yu CJ, Panda SS, et al. Epithelial cell adhesion molecule (EpCAM) regulates HGFR signaling to promote colon cancer progression and metastasis. J Transl Med. 2023;21(1):530.

[42] Lim SB, Tan SJ, Lim WT, et al. An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer. Nat Commun. 2017;8(1):1734.

[43] Xiao L, Li Q, Huang Y, et al. Integrative analysis constructs an extracellular matrix-associated gene signature for the prediction of survival and tumor immunity in lung adenocarcinoma. Front Cell Dev Biol. 2022;10:835043.

[44] Graziani V, Rodriguez-Hernandez I, Maiques O, et al. The amoeboid state as part of the epithelial-to-mesenchymal transition programme. Trends Cell Biol. 2022;32(3):228-242.

[45] Fagotto F, Aslemarz A. EpCAM cellular functions in adhesion and migration, and potential impact on invasion: a critical review. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188436.

[46] Zhang L, Zhang Y, Li X, et al. CircRNA-miRNA-VEGFA: an important pathway to regulate cancer pathogenesis. Front Pharmacol. 2023;14:1049742.

[47] Hayashi Y, Yokota A, Harada H, et al. Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible factor-1α in cancer. Cancer Sci. 2019;110(5):1510-1517.

[48] Shi X, Leng L, Wang T, et al. CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity. 2006;25(4):595-606.

[49] Hou J, Mi X, Liu N, et al. Albumin paclitaxel combined with intrapleural infusion of bevacizumab + lobaplatin for the second-line treatment of patients with non-squamous non-small cell lung cancer. J Oncol. 2022;2022:5901450.

[50] Du N, Li X, Li F, et al. Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer‑mediated malignant pleural effusion. Oncol Rep. 2013;29(6):2332-2340.

[51] Tariq M, Hussain N, Rehman K, et al. Macrophages M2 polarization is involved in lapatinib-mediated chemopreventive effects in the lung cancer. Biomed Pharmacother. 2023;161:114527.

[52] Chen Y, Song J, Ruan Q, et al. Single-cell sequencing methodologies: from transcriptome to multi-dimensional measurement. Small Methods. 2021;5(6):e2100111.

[53] Bang C, Park MG, Cho IK, et al. Liposomes targeting the cancer cell-exposed receptor, claudin-4, for pancreatic cancer chemotherapy. Biomater Res. 2023;27(1):53.

[54] Yamamoto TM, Webb PG, Davis DM, et al. Loss of Claudin-4 reduces DNA damage repair and increases sensitivity to PARP inhibitors. Mol Cancer Ther. 2022;21(4):647-657.

[55] Luo Y, Kishi S, Sasaki T, et al. Targeting claudin-4 enhances chemosensitivity in breast cancer. Cancer Sci. 2020;111(5):1840-1850.

[56] Song Y-X, Sun J-X, Zhao J-H, et al. Non-coding RNAs participate in the regulatory network of CLDN4 via ceRNA mediated miRNA evasion. Nat Commun. 2017;8(1):289.

[57] Lin X, Shang X, Manorek G, et al. Regulation of the epithelial-mesenchymal transition by Claudin-3 and Claudin-4. PLoS One. 2013;8(6):e67496.

[58] Yan T, Tan Y, Deng G, et al. TGF-β induces GBM mesenchymal transition through upregulation of CLDN4 and nuclear translocation to activate TNF-α/NF-κB signal pathway. Cell Death Dis. 2022;13(4):339.

[59] Facchetti F, Lonardi S, Gentili F, et al. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions. Virchows Arch. 2007;451(3):669-680.

[60] Lonardi S, Manera C, Marucci R, et al. Usefulness of Claudin 4 in the cytological diagnosis of serosal effusions. Diagn Cytopathol. 2011;39(5):313-317.

[61] Ibrahim FM, Helal DS, Ali DA, et al. Prognostic role of annexin A2 and cancer-associated fibroblasts in advanced non-small cell lung cancer: implication in epithelial-mesenchymal transition and gefitinib resistance. Pathol Res Pract. 2023;241:154293.

[62] Xu J, Zhang W. EZR promotes pancreatic cancer proliferation and metastasis by activating FAK/AKT signaling pathway. Cancer Cell Int. 2021;21(1):521.

[63] Kuang L, Li L. E74-like factor 3 suppresses microRNA-485-5p transcription to trigger growth and metastasis of ovarian cancer cells with the involvement of CLDN4/Wnt/β-catenin axis. Saudi J Biol Sci. 2021;28(8):4137-4146.

[64] Horie M, Tanaka H, Suzuki M, et al. An integrative epigenomic approach identifies ELF3 as an oncogenic regulator in ASCL1-positive neuroendocrine carcinoma. Cancer Sci. 2023;114(6):2596-2608.

[65] Zhu H, Yan S, Wu J, et al. Serum macrophage migration inhibitory factor as a potential biomarker to evaluate therapeutic response in patients with allergic asthma: an exploratory study. J Zhejiang Univ Sci B. 2021;22(6):512-520.

[66] Klemke L, De Oliveira T, Witt D, et al. Hsp90-stabilized MIF supports tumor progression via macrophage recruitment and angiogenesis in colorectal cancer. Cell Death Dis. 2021;12(2):155.

[67] Mahalingam D, Patel MR, Sachdev JC, et al. Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. Br J Clin Pharmacol. 2020;86(9):1836-1848.

[68] Noro R, Kobayashi K, Usuki J, et al. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: a phase II study North East Japan Study group trial NEJ013B. Thorac Cancer. 2020;11(7):1876-1884.

[69] Zhang M, Yan L, Lippi G, et al. Pleural biomarkers in diagnostics of malignant pleural effusion: a narrative review. Transl Lung Cancer Res. 2021;10(3):1557-1570.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.